VRC01LS
VRC01LS is a humanized monoclonal antibody inhibitor targeting the CD4-binding site of HIV-1 envelope glycoprotein (Env) . VRC01LS blocks the binding of HIV-1 to host cell CD4 receptor, inhibiting viral entry. VRC01LS is promising for research of HIV-1 infection[1][2].
Product Specifications
UNSPSC
12352203
Target
HIV; Virus Protease
Related Pathways
Anti-infection
Applications
COVID-19-anti-virus
Field of Research
Infection
Purity
98.78
Smiles
[VRC01LS]
Molecular Weight
(145.94 kDa)
References & Citations
[1]Happe M, et al. Virologic effects of broadly neutralizing antibodies VRC01LS and VRC07-523LS on chronic HIV-1 infection. JCI Insight. 2025 Feb 24;10 (4) :e181496.|[2]Gaudinski MR, et al. Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults. PLoS Med. 2018 Jan 24;15 (1) :e1002493.
Shipping Conditions
Dry Ice
Storage Conditions
-80°C
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 2
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
GTR15241403 1 Vial
Lentiviral mouse Csl shRNA (UAS) - Lentiviral mouse Csl shRNA (UAS, RFP) (25)
Sign In for Pricing
View Details 
MBS2011703-01 0.01 mg
Recombinant Vascular Endothelial Growth Factor A (VEGFA)
Sign In for Pricing
View Details MBS2011703-02 0.05 mg
Recombinant Vascular Endothelial Growth Factor A (VEGFA)
Sign In for Pricing
View Details MBS2011703-03 0.1 mg
Recombinant Vascular Endothelial Growth Factor A (VEGFA)
Sign In for Pricing
View Details MBS2011703-04 0.2 mg
Recombinant Vascular Endothelial Growth Factor A (VEGFA)
Sign In for Pricing
View Details